have shown that selenium‐avid cancer cells employ SLC7A11 (a constituent of the cystine/glutamate antiporter SLC7A11) and xCT to facilitate increased selenium uptake (Carlisle et al. 2020), This, in turn, enables cancer cells to synthesize GPX4. Here, SLC7A11 is linked to cancer.